The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study
There is increasing interest in using genetic tests and other biomarkers to identify individuals at-risk for Alzheimer’s disease (AD). However, given the current limitations of predictive testing and AD treatment capabilities, there is much debate about how and whether to disclose such risk information. The Risk Evaluation & Education for Alzheimer’s Disease (REVEAL) Study is a series of successive, multi-site randomized clinical trials that has examined the psychological and behavioral impact of providing genetic risk assessment to at-risk populations. Led by Head Principal Investigator, Robert C. Green, M.D., M.P.H., at Harvard / Brigham & Women’s Hospital and continuously funded by the National Institutes of Health since 1999, the REVEAL Study has used APOE genotype disclosure as means to provide personalized AD risk information to interested participants and has tested different methods of delivering this information.
The study is now in its fourth trial, with sites at Harvard / Brigham & Women’s Hospital, Howard University, the University of Pennsylvania, and the University of Michigan. The focus of the current trial is individuals with Mild Cognitive Impairment, a common condition that often (but not always) is a precursor to clinical AD. Given that APOE genotype is associated with different rates of progression from MCI to AD, we are examining issues involved in estimating and communicating genetic risk information to people with MCI.
The REVEAL IV study aims to: (1) develop a risk communication protocol for persons with mild cognitive impairment (MCI) and (2) examine the psychological and behavioral impact of disclosing APOE genotype and 3-year risk estimates to persons with MCI and their study partners.
To view a YouTube video about the study, click here.
The REVEAL study is funded by an R01 grant (HG02213) from the National Human Genome Research Institute (NHGRI) and the National Institute on Aging (NIA).